Recombinant E. coli for 1,3-butanediol production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioprocessing methods for producing 1,3-butanediol (1,3-BDO) from glucose are inefficient, with low productivity and economic feasibility, and are hindered by the lack of a naturally occurring metabolic pathway for 1,3-BDO production.
Innovation Solution
Development of a recombinant E. coli strain with a cloned gene pathway for biosynthesizing 1,3-BDO from acetyl-CoA and optimized pathways for glucose conversion to acetyl-CoA, enhancing biosynthetic efficiency, regeneration rate of NADPH, and efficient utilization of TCA cycles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If biocatalytic process is used to produce 1,3-BDO, then environmental friendliness and renewability are improved, but productivity and economic feasibility deteriorate
Solution Approach 1:
The patent segments the metabolic pathway into distinct functional modules: glucose metabolism module (glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase), acetyl-CoA synthesis module (pyruvate dehydrogenase), and 1,3-BDO synthesis module (acetyl-CoA acetyltransferase, acetoacetyl-CoA reductase, 3-hydroxybutyraldehyde reductase). This segmentation allows independent optimization of each module to achieve both environmental friendliness and high productivity.
Solution Approach 2:
The patent merges multiple metabolic pathways into a single integrated recombinant E. coli strain. It combines the pentose phosphate pathway, glycolysis, TCA cycle, and 1,3-BDO synthesis pathway into one coordinated system, enabling simultaneous production of 1,3-BDO with high yield and productivity while maintaining environmental benefits.
2Adaptability or versatility
If recombinant bacterial strains are developed for 1,3-BDO production, then naturalness and renewability are improved, but titer, productivity, and yield deteriorate
Solution Approach 1:
The patent changes multiple metabolic parameters simultaneously: it modifies the expression levels of key enzymes (glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, pyruvate dehydrogenase, acetyl-CoA acetyltransferase, acetoacetyl-CoA reductase, 3-hydroxybutyraldehyde reductase), adjusts cofactor ratios (NADPH/NADP+), and optimizes pathway flux distributions. These parameter changes enable the strain to achieve high titer (80 g/L) while maintaining natural metabolic processes.
3Device complexity
If existing metabolic pathways are used for 1,3-BDO production, then process simplicity is maintained, but biosynthetic efficiency and yield deteriorate
Solution Approach 1:
The patent performs preliminary metabolic engineering actions by pre-optimizing the expression of key enzymes and pre-establishing efficient pathway connections before actual 1,3-BDO production. It pre-regulates the activity of glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and other metabolic enzymes to ensure optimal biosynthetic efficiency from the start of production.
Solution Approach 2:
The patent implements feedback mechanisms through metabolic regulation, where the activity of key enzymes is dynamically adjusted based on substrate availability and product formation. The system monitors and regulates flux through the pentose phosphate pathway, glycolysis, and TCA cycle to maintain optimal biosynthetic efficiency throughout the production process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant E. coli strain achieves high concentrations, yields, and rates of 1,3-butanediol production, with a maximum concentration of 80 g/L, a glucose yield of 0.74 mol/mol, and a production rate of 1.67 g/L/h.
Implementation Method 1
a recombinant E. coli strain in which a gene of a pathway required for biosynthesizing 1,3-BDO from acetyl-CoA is cloned and from which a gene of a pathway that interferes with or competes with the pathway is removed
Implementation Method 2
modified and optimized pathways and genes involved in conversion of glucose to acetyl-CoA that is required to improve biosynthetic efficiency of 1,3-BDO, regeneration rate of NADPH which is used as a cofactor
Implementation Method 3
efficient utilization of TCA cycles
Data Source
AI summary
The present invention relates to a recombinant E. coli strain producing 1,3-butanediol from glucose and a method for producing 1,3-butanediol using same, in which a recombinant E. coli strain was developed in which a gene of a pathway necessary for biosynthesis of 1,3-BDO from acetyl-CoA is cloned, and a gene of a pathway that interferes with or competes with this pathway is removed, wherein an E. coli strain was developed in which the pathways and genes involved in the conversion of glucose to acetyl COA, the regeneration rate of NADPH used as a cofactor, and the efficient use of the TCA cycle pathway, which are necessary to improve the biosynthetic efficiency of 1,3-BDO, are modified and optimized.